Last reviewed · How we verify
NCT04141397
Real-world Clinical Effectiveness of Whole Genome and Transcriptome Analysis to Guide Advanced Cancer Care
trial testing Initiation of POG-related WGTA in Metastatic Cancer in 1,200 participants. Status unknown.
31 December 2018
Quick facts
| Lead sponsor | British Columbia Cancer Agency |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 1,200 |
| Start date | 1 July 2014 |
| Primary completion | 31 December 2018 |
| Estimated completion | 31 December 2021 |
Drugs / interventions tested
- Initiation of POG-related WGTA
- Usual care
Conditions studied
- Metastatic Cancer — all drugs for Metastatic Cancer →
- Advanced Cancer — all drugs for Advanced Cancer →
- Cancers That Cannot be Treated With Curative Intent — all drugs for Cancers That Cannot be Treated With Curative Intent →
Sponsor
British Columbia Cancer Agency
Who can join
Adults 19 to 85, any sex, with Metastatic Cancer or Advanced Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to determine the clinical effectiveness of whole-genome and transcriptome analysis (WGTA) to guide advanced cancer care. The study setting is the British Columbia (BC) Personalized OncoGenomics (POG) program, a single group research study of WGTA guiding treatment planning for patients with advanced, incurable cancers (NCT02155621). To characterize clinical effectiveness, the survival impacts of POG's approach compared to usual care in matched controls will be estimated.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04141397
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Metastatic Cancer
Currently open trials in the same condition.
- NCT06346197 — Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas · Phase 3 · recruiting
- NCT07144085 — Application of ⁶⁸Ga-FXX489 (NNS309) PET/CT Imaging in Diagnosis of Tumor Diseases. · Phase 1 · recruiting
- NCT06963723 — Longitudinal Screening for Financial Hardship to Improve Outcomes in Patients With Advanced Cancer · NA · recruiting
- NCT06311851 — Transarterial Chemoembolization (TACE) Plus Bevacizumab for Liver Metastases · Phase 1, PHASE2 · recruiting
- NCT07011862 — COBRA: Cancer, Older Adults, Balance and Resistance Activities · NA · recruiting
Other British Columbia Cancer Agency trials
Trials by the same sponsor.
- NCT07295171 — HELP Study - Towards High Throughput and Efficient Long-axial PET With Oral [18F]FDG · NA · recruiting
- NCT07291895 — High Dose Radiotherapy for Palliation (Hi-D) · NA · not yet recruiting
- NCT06918951 — Stereotactic Radiotherapy Versus Palliative Conventional Radiotherapy for Oligoprogressive Metastatic Cancers · NA · recruiting
- NCT07210749 — Radiotherapy 12Gy in 6 Fractions For Orbital Lymphoma · NA · not yet recruiting
- NCT06835725 — Phase II Randomized Trial of 2 Versus 5 Fraction Prostate Stereotactic Ablative Radiotherapy for Intermediate Risk Prost · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04141397 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by British Columbia Cancer Agency
- Last refreshed: 27 January 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04141397.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing